中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

45 records (took 0.053 seconds)

    암의 증식, 재발 또는 전이 억제용 의약 조성물
    11.
    发明公开
    암의 증식, 재발 또는 전이 억제용 의약 조성물 无效
    用于抑制癌症生长，复发或转移的药物组合物

    公开(公告)号：KR1020130064162A

    公开(公告)日：2013-06-18

    申请号：KR1020110130483

    申请日：2011-12-07

    Applicant: 한올바이오파마주식회사

    Inventor： 문애리 ,  고민수 ,  민창희 ,  이순임

    IPC: A61K31/53

    CPC classification number: A61K31/53

    Abstract: PURPOSE: A pharmaceutical composition for suppressing recurrence, proliferation, or metastasis of cancer is provided to effectively suppress proliferation, recurrence, or metastasis of cancer by suppressing cancer cell invasion. CONSTITUTION: A pharmaceutical composition for suppressing recurrence, proliferation, or metastasis of cancer contains a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The cancer is selected from the group consisting of breast cancer, uterine cancer, stomach cancer, brain cancer, rectal cancer, colon cancer, lung cancer, skin cancer, blood cancer, and liver cancer. The composition is simultaneously or sequentially administered with an anticancer agent.

    Abstract translation: 目的：提供抑制癌症复发，增殖或转移的药物组合物，以通过抑制癌细胞侵袭来有效抑制癌症的增殖，复发或转移。 构成：用于抑制癌症复发，增殖或转移的药物组合物含有化学式1的化合物或其药学上可接受的盐; 和药学上可接受的载体。 癌症选自乳腺癌，子宫癌，胃癌，脑癌，直肠癌，结肠癌，肺癌，皮肤癌，血癌和肝癌。 该组合物同时或依次施用抗癌剂。

    암의 재발 또는 전이의 억제용 약제학적 조성물
    13.
    发明公开
    암의 재발 또는 전이의 억제용 약제학적 조성물 审中-实审
    用于抑制癌症复发或METASTASIS的药物组合物

    公开(公告)号：KR1020130015669A

    公开(公告)日：2013-02-14

    申请号：KR1020110077794

    申请日：2011-08-04

    Applicant: 한올바이오파마주식회사

    Inventor： 김성욱 ,  민창희 ,  구자성 ,  선상욱 ,  김용은

    IPC: A61K31/70 ,  A61K31/7004 ,  A61P35/00

    CPC classification number: A61K45/06 ,  A61K9/2054 ,  A61K31/155 ,  A61K31/4015 ,  A61K31/7004 ,  A61K2300/00

    Abstract: PURPOSE: A pharmaceutical composition for suppressing cancer recurrence or metastasis is provided to reduce side effects and to enable effective treatment. CONSTITUTION: A pharmaceutical composition for suppressing cancer recurrence or metastasis contains 10-4000 mg of 2-deoxy-D-gluscose as an active ingredient. The pharmaceutical composition contains a biguanide-based therapeutic agent for treating diabetes or a pharmaceutically acceptable salt thereof, and 2-deoxy-D-gluscose as active ingredients. The therapeutic agent is metformin, phenformin, or buformin. The pharmaceutically acceptable salt of metformin is hydrochloride or acetate. The pharmaceutical composition is an oral formulation or a parenteral formulation. The pharmaceutical composition additionally contains an anticancer agent as an active ingredient. The cancer is colon cancer or breast cancer. [Reference numerals] (AA) Mammosphere formation; (BB) Hydrochloride of metformin; (CC) Hydrochloride of metformin + 2-DG

    Abstract translation: 目的：提供用于抑制癌症复发或转移的药物组合物，以减少副作用并有效治疗。 构成：用于抑制癌症复发或转移的药物组合物含有10-4000mg的2-脱氧-D-果糖作为活性成分。 药物组合物含有用于治疗糖尿病的双胍类治疗剂或其药学上可接受的盐，作为活性成分含有2-脱氧-D-果糖。 治疗剂是二甲双胍，苯乙双胍或丁福明。 二甲双胍的药学上可接受的盐是盐酸盐或乙酸盐。 药物组合物是口服制剂或肠胃外制剂。 药物组合物另外含有抗癌剂作为有效成分。 癌症是结肠癌或乳腺癌。 （附图标记）（AA）哺乳动物圈形成; （BB）盐酸二甲双胍; （CC）盐酸二甲双胍+ 2-DG

    Ｎ,Ｎ-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
    16.
    发明公开
    Ｎ,Ｎ-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제 无效
    N，N-二甲基咪唑二恶烷二酸酯，其制备方法，包含其的药物组合物和包括其的组合制剂

    公开(公告)号：KR1020120031288A

    公开(公告)日：2012-04-02

    申请号：KR1020120016856

    申请日：2012-02-20

    Applicant: 한올바이오파마주식회사

    Inventor： 김성욱 ,  전성수 ,  민창희 ,  구자성 ,  강민석 ,  김용은

    IPC: C07C279/26 ,  C07C53/122 ,  A61K31/155 ,  A61P3/10

    CPC classification number: C07C53/122 ,  C07C277/00 ,  C07C279/26

    Abstract: PURPOSE: A N,N-dimethyl imidodicarbonimidic diamide propionate is provided to have excellent solubility, stability, non-hygroscopicity, adhesion preventing properties, processability, and pharmacological effects, and can be manufactured under mild conditions with high yield. CONSTITUTION: The N,N-dimethyl imidodicarbonimidic diamide propionate is in chemical formula 1, and has the melting point of the crystal structure in chemical formula 1 which is 194 - 194.5 °C. The manufacturing method of the N,N-dimethyl imidodicarbonimidic diamide propionate in chemical formula 1 comprises a step of manufacturing the metformin glass base in chemical formula 3 by reacting the metformin hydrochloride in chemical formula 2 with a base under organic solvent, and a step of reacting the metformin glass base with propionic acid.

    Abstract translation: 目的：提供N，N-二甲基亚氨基二酰亚胺二酰丙酸丙酸酯具有优异的溶解性，稳定性，不吸湿性，防粘连性，加工性和药理作用，可以在温和条件下以高产率制备。 构成：化学式1中的N，N-二甲基亚氨基二酰亚胺二酰胺丙酸酯为化学式1中的结晶结构的熔点为194-194.5℃。 化学式1中的N，N-二甲基亚氨基二亚氨基二酰丙酸丙酸酯的制造方法包括通过化学式2中的二甲双胍盐酸盐与有机溶剂中的碱反应制造化学式3中的二甲双胍玻璃碱的步骤， 二甲双胍玻璃碱与丙酸反应。

    난용성 약물을 함유하는 경구 제형
    17.
    发明公开
    난용성 약물을 함유하는 경구 제형 有权
    口服固体剂型，包含不溶性药物

    公开(公告)号：KR1020110085307A

    公开(公告)日：2011-07-27

    申请号：KR1020100005016

    申请日：2010-01-20

    Applicant: 한올바이오파마주식회사

    Inventor： 민창희 ,  구자성 ,  장석영 ,  이길호

    IPC: A61K47/38 ,  A61K31/4184 ,  A61K31/41 ,  A61K9/20

    CPC classification number: A61K47/38 ,  A61K9/0053 ,  A61K31/4184 ,  A61K47/02

    Abstract: PURPOSE: An oral formulaion containing telmisartan is provided to ensure formulation stability and to improve release profile. CONSTITUTION: A pharmaceutical composition contains insoluble drugs or pharmaceutically acceptable salt thereof, and water insoluble diluent. The insoluble drug is telmisartan. The pharmaceutical composition additionally contains alkylating agent and stabilizing agent. The alkylating agent is inorganic or organic. The stabilizing agent is cellulose derivative-based stabilizer such as hydroxypropyl cellulose, hydroxymethyl cellulose, or hydroxyethyl cellulose.

    Abstract translation: 目的：提供含替米沙坦的口服制剂以确保制剂的稳定性和改善释放特征。 构成：药物组合物含有不溶性药物或其药学上可接受的盐和水不溶性稀释剂。 不溶性药物是替米沙坦。 药物组合物另外含有烷化剂和稳定剂。 烷基化剂是无机或有机的。 稳定剂是纤维素衍生物类稳定剂，如羟丙基纤维素，羟甲基纤维素，或羟乙基纤维素。

    메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
    18.
    发明公开
    메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 无效
    甲基麦芽糖苷，其制备方法，包含其的药物组合物和包含其的组合制剂

    公开(公告)号：KR1020110021691A

    公开(公告)日：2011-03-04

    申请号：KR1020100082553

    申请日：2010-08-25

    Applicant: 한올바이오파마주식회사

    Inventor： 김성욱 ,  전성수 ,  민창희 ,  구자성 ,  강민석 ,  김용은

    IPC: C07C279/26 ,  C07C309/02 ,  A61K31/155 ,  A61P3/10

    CPC classification number: C07C309/04 ,  C07C279/26

    Abstract: PURPOSE: A metformin methanesulfonate and a pharmaceutical composition comprising the same are provided to ensure excellent activation of AMPKα, relatively low toxicity, stability, and non-hygroscopic property. CONSTITUTION: A metformin methanesulfonate represented by chemical formula 1 has a melting point of 194.0~194.5 °C. A pharmaceutical composition contains the metformin methanesulfonic acid salt as an active ingredient. The metformin methanesulfonate can be effectively used in treating glycosuria, diabetes, metabolic syndrome, diabetes complications, menstrual irregularities, hypertension, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome, cancer, myalgia, symptoms of muscle cell cytotoxicity, rhabdomyolysis and/or climacterium, etc.

    Abstract translation: 目的：提供二甲双胍甲磺酸盐和包含其的药物组合物以确保AMPKα的优异活化，相对低毒性，稳定性和非吸湿性。 构成：由化学式1表示的二甲双胍甲磺酸盐的熔点为194.0〜194.5℃。 药物组合物含有二甲双胍甲磺酸盐作为活性成分。 二甲双胍甲磺酸盐可有效用于治疗糖尿病，糖尿病，代谢综合征，糖尿病并发症，月经不调，高血压，高脂血症，脂肪肝，冠状动脉疾病，骨质疏松症，多囊卵巢综合征，癌症，肌痛，肌肉细胞毒性症状，横纹肌溶解 和/或气候等

    스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
    19.
    发明公开
    스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 无效
    包含LOSARTAN用于治疗或预防静脉诱导的肌肉毒性的药物组合物

    公开(公告)号：KR1020130074808A

    公开(公告)日：2013-07-05

    申请号：KR1020110136687

    申请日：2011-12-16

    Applicant: 한올바이오파마주식회사

    Inventor： 김성욱 ,  최성준 ,  민창희 ,  이순임 ,  구자성 ,  선상욱 ,  이나영

    IPC: A61K31/41 ,  A61K31/4164 ,  A61P21/00

    CPC classification number: A61K31/4178 ,  A61K31/00 ,  A61K31/351 ,  A61K31/402

    Abstract: PURPOSE: A pharmaceutical composition containing losartan or a pharmaceutically acceptable salt thereof is provided to ensure a pharmacological effect for preventing or treating hypertension, and to prevent or treat muscle-related side effects caused by administration of statin-based drug. CONSTITUTION: A pharmaceutical composition for preventing or treating muscle toxicity due to a statin-based lipid lowering agent contains losartan or a pharmaceutically acceptable salt thereof as an active ingredient. Losartan or the pharmaceutically acceptable salt is simultaneously and sequentially administered with the statin-based lipid lowering agent. The pharmaceutical composition is also used for preventing or treating hypertension. The muscle toxicity is one or more side effects selected from the group consisting of myositis, myopathy, rhabdomyolysis, and myalgia. [Reference numerals] (AA) CK concentration change rate (%); (BB) Administration time (week); (CC) 40mg/kg of atorvastatin administration group; (DD) 40mg/kg of atorvastatin + 100mg/kg of losartan simultaneous administration group; (EE) 80mg/kg of atorvastatin administration group; (FF) 80mg/kg of atorvastatin + 200mg/kg of losartan simultaneous administration group; (GG) 80mg/kg of atorvastatin + 200mg/kg of losartan time interval administration group

    Abstract translation: 目的：提供含有氯沙坦或其药学上可接受的盐的药物组合物，以确保预防或治疗高血压的药理作用，以及预防或治疗由给予他汀类药物引起的肌肉相关副作用。 构成：用于预防或治疗由于基于他汀类的降脂剂引起的肌肉毒性的药物组合物含有氯沙坦或其药学上可接受的盐作为活性成分。 氯沙坦或其药学上可接受的盐同时并依次给予他汀类降脂药。 药物组合物也用于预防或治疗高血压。 肌肉毒性是选自肌炎，肌病，横纹肌溶解症和肌痛的一种或多种副作用。 （附图标记）（AA）CK浓度变化率（％） （BB）行政时间（周）; （CC）40mg / kg阿托伐他汀给药组; （DD）40mg / kg阿托伐他汀+ 100mg / kg氯沙坦同时给药组; （EE）80mg / kg阿托伐他汀给药组; （FF）80mg / kg阿托伐他汀+ 200mg / kg氯沙坦同时给药组; （GG）80mg / kg阿托伐他汀+ 200mg / kg氯沙坦时间间隔给药组

Patent Agency Ranking